A Phase 1b/2 Trial Investigating the Safety and Efficacy of Oral AMXT 1501 and Oral DFMO in Combination With Standard of Care in Patients With Advanced Solid Tumors Who Progressed After Prior Therapies

This study is testing a new combination of oral medications (AMXT 1501 and DFMO) alongside standard treatments to see if they can better stop the growth of advanced breast cancer or melanoma. Researchers are looking for safer, more effective ways to help patients whose cancer has continued to grow after previous treatments.

You may be eligible if you are at least 18 years old and have been diagnosed with either hormone-positive/HER2-negative breast cancer or advanced melanoma. You must have already tried other treatments that did not stop your cancer from progressing.

Participants will take the study drugs daily alongside their standard cancer therapy while doctors monitor their health and the tumor's response. The team will perform regular check-ups to track how you feel, record any side effects, and see how well the medicine is working.

This study is currently recruiting patients at medical centers in Tucson, Arizona; Los Angeles, California; and Englewood, Colorado. You should speak with your doctor to see if one of these locations is accessible for your care.